

RELISA® ENA

For *her*, a correct diagnosis depends on your ENA results.
For *you*, correct ENA results depend on your supplier.
You can *both* depend on RELISA® for your ENA results.

A flexible test menu to fit your needs

- The RELISA® Single Well Screen offers laboratories the cost-saving option of efficiently screening out the samples that are negative for antibodies to extractable nuclear antigens (ENA). Positive samples are then tested for specific antibodies.
- The RELISA® ENA Multi-parameter test system tests for antibodies to Sm, RNP, SSA/Ro (Ro60 and Ro52), SSB/La, Scl-70 & Jo-1 in individual wells on a single strip.
- The RELISA® ENA Single Parameter test system allows testing with only the ENAs you need.

Did you know early symptoms of the Systemic Rheumatic Diseases (SRD) can be very similar to other diseases? However, different diseases may require different treatments and hold a very different prognosis for the patient.¹

Early identification of these autoantibodies can lead to an earlier diagnosis and an improved prognosis for the patient.

She is counting on you to turn out the correct result.

Call today to schedule your in-house demonstration, and start to make a difference in the lives of these patients.



1. Conrad K, Schöblier W, Hiepe F, Fritzler M. Autoantibodies in Systemic Autoimmune Diseases, A Diagnostic Reference. Vol 2. 2nd ed. Lengerich: Pabst Science Publishers; 2007.

RELISA® ENA Products

A family of products that you can rely on

- Easily automated
 - Break-away wells
 - Affinity purified antigens
 - Optional assayed control is included
- The RELISA® ENA Single Well Screen and Single Parameter Kits feature a single point calibration that conserves test wells in each run. The RELISA® ENA Multi-Parameter Kit features a built-in control for each strip.

ANTIGEN	DISEASE	ASSOCIATED CLINICAL FEATURES
Sm	SLE	Diagnostic marker for SLE. Prognostic marker for severe internal organ involvement.
RNP (U1-RNP)	MCTD, SLE, SSc	Diagnostic criterion for MCTD. Discoid lesions in SLE. Pulmonary fibrosis in SSc.
SSA/Ro	SjS, SLE, SCLE, NLE, SSc	Diagnostic marker for SjS. Associated with NLE and CHB in newborns. Severe SSc. Presence can precede symptoms by years.
SSB/La	SjS, SLE, NLE, SCLE	Diagnostic marker of SjS. Less kidney damage in SLE. CHB in newborns.
Scl-70 (Topoisomerase II)	SSc	Diagnostic marker for SSc. Prognostic marker of a more severe disease. Presence can precede symptoms by years.
Jo-1	Myositis	Diagnostic criterion for autoimmune myositis.

KEY

Systemic Lupus Erythematosus (SLE)
Subacute cutaneous lupus (SCLE)

Mixed Connective Tissue Disease (MCTD)
Neonatal Lupus Erythematosus (NLE)

Systemic Sclerosis (SSc)
Sjögren's Syndrome (SjS)

Table adapted from: Conrad K, Schöbler W, Hiepe F, Fritzler M. Autoantibodies in Systemic Autoimmune Diseases, A Diagnostic Reference. Vol 2. 2nd ed. Lengerich: Pabst Science Publishers; 2007

Ordering information:

7096-10	RELISA® ENA Single Well Screen Kit	96 wells
7096-09	RELISA® ENA Multi-parameter Kit*	96 wells
7096-09.Sm	RELISA® ENA Sm Test Kit	96 wells
7096-09.Sm-RNP	RELISA® ENA Sm/RNP Test Kit	96 wells
7096-09.SSA	RELISA® ENA SSA Test Kit	96 wells
7096-09.SSB	RELISA® ENA SSB Test Kit	96 wells
7096-09.Scl-70	RELISA® ENA Scl-70 Test Kit	96 wells
7096-09.Jo-1	RELISA® ENA Jo-1 Test Kit	96 well

*Optional assayed control is not included



Immuno Concepts N.A. Ltd.
9825 Goethe Road, Suite 350, Sacramento, CA 95827
916.363.2649 | 800.251.5115
www.immunoconcepts.com